Irinotecan and oxaliplain : an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer
Autor(a) principal: | |
---|---|
Data de Publicação: | 2001 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/21166 |
Resumo: | Colorectal cancer is one of the most frequent malignancies in humans and an important cause of cancer death. Metastatic colorectal cancer remains incurable with available systemic therapeutic options. The most active cytotoxic drug against this malignancy, the antimetabolite 5-fluorouracil, was developed more than forty years ago, and as a single agent produces responses in only 10 to 15% of patients which in general last less than one year. Efforts to ameliorate these poor results resulted in the 5-fluorouracil/leucovorin combination, which enhances response rates about two-fold, without, however, significantly improving survival rates. The recent emergence of a handful of new 5- fluorouracil analogues and folate antagonists, as well as the topoisomerase I inhibitor irinotecan, and the third-generation platinum compound oxaliplatin, is likely to alter this gloomy scenario. These agents are at least as effective as 5-fluorouracil in patients with advanced colorectal carcinoma, both untreated and previously treated with 5- fluorouracil-based regimens. This has led to the approval of irinotecan as second-line treatment for 5-fluorouracil-refractory disease, while the use of oxaliplatin has been suggested for patients having a defective 5-fluorouracil catabolism. Recently, FDA approved the combination of irinotecan with 5-fluorouracil and leucovorin for first-line treatment of advanced colon cancer. Based on the synergistic preclinical antitumor effects of some of these agents, their meaningful singleagent activity, distinct mechanisms of cytotoxicity and resistance, and only partially overlapping toxicity profiles, effective combination regimens are now being developed, which are likely to lead to a new, more hopeful era for patients suffering from advanced colorectal carcinoma. |
id |
UFRGS-2_85e6557060dfa55d5410d4bd7115d32a |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/21166 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Grivicich, IvanaMans, Dennis Ricardo AugustPeters, Godefridus J.Schwartsmann, Gilberto2010-04-24T04:15:33Z20010100-879Xhttp://hdl.handle.net/10183/21166000341742Colorectal cancer is one of the most frequent malignancies in humans and an important cause of cancer death. Metastatic colorectal cancer remains incurable with available systemic therapeutic options. The most active cytotoxic drug against this malignancy, the antimetabolite 5-fluorouracil, was developed more than forty years ago, and as a single agent produces responses in only 10 to 15% of patients which in general last less than one year. Efforts to ameliorate these poor results resulted in the 5-fluorouracil/leucovorin combination, which enhances response rates about two-fold, without, however, significantly improving survival rates. The recent emergence of a handful of new 5- fluorouracil analogues and folate antagonists, as well as the topoisomerase I inhibitor irinotecan, and the third-generation platinum compound oxaliplatin, is likely to alter this gloomy scenario. These agents are at least as effective as 5-fluorouracil in patients with advanced colorectal carcinoma, both untreated and previously treated with 5- fluorouracil-based regimens. This has led to the approval of irinotecan as second-line treatment for 5-fluorouracil-refractory disease, while the use of oxaliplatin has been suggested for patients having a defective 5-fluorouracil catabolism. Recently, FDA approved the combination of irinotecan with 5-fluorouracil and leucovorin for first-line treatment of advanced colon cancer. Based on the synergistic preclinical antitumor effects of some of these agents, their meaningful singleagent activity, distinct mechanisms of cytotoxicity and resistance, and only partially overlapping toxicity profiles, effective combination regimens are now being developed, which are likely to lead to a new, more hopeful era for patients suffering from advanced colorectal carcinoma.application/pdfporBrazilian journal of medical and biological research. Ribeirão Preto, SP. Vol. 34, no. 9 (Sept. 2001), p. 1087-1103Neoplasias colorretaisColorectal carcinoma5-FluorouracilIrinotecanOxaliplatinIrinotecan and oxaliplain : an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancerinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/otherinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSORIGINAL000341742.pdf000341742.pdfTexto completoapplication/pdf83472http://www.lume.ufrgs.br/bitstream/10183/21166/1/000341742.pdf26f56908bce4169f52adaeefe6a1107eMD51TEXT000341742.pdf.txt000341742.pdf.txtExtracted Texttext/plain67212http://www.lume.ufrgs.br/bitstream/10183/21166/2/000341742.pdf.txte49979af593af239a2ca0b8dd720e168MD52THUMBNAIL000341742.pdf.jpg000341742.pdf.jpgGenerated Thumbnailimage/jpeg1706http://www.lume.ufrgs.br/bitstream/10183/21166/3/000341742.pdf.jpg8af6ac8c67a140350fdd161aa5d8bbf5MD5310183/211662023-11-10 04:25:28.739901oai:www.lume.ufrgs.br:10183/21166Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2023-11-10T06:25:28Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Irinotecan and oxaliplain : an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer |
title |
Irinotecan and oxaliplain : an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer |
spellingShingle |
Irinotecan and oxaliplain : an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer Grivicich, Ivana Neoplasias colorretais Colorectal carcinoma 5-Fluorouracil Irinotecan Oxaliplatin |
title_short |
Irinotecan and oxaliplain : an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer |
title_full |
Irinotecan and oxaliplain : an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer |
title_fullStr |
Irinotecan and oxaliplain : an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer |
title_full_unstemmed |
Irinotecan and oxaliplain : an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer |
title_sort |
Irinotecan and oxaliplain : an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer |
author |
Grivicich, Ivana |
author_facet |
Grivicich, Ivana Mans, Dennis Ricardo August Peters, Godefridus J. Schwartsmann, Gilberto |
author_role |
author |
author2 |
Mans, Dennis Ricardo August Peters, Godefridus J. Schwartsmann, Gilberto |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Grivicich, Ivana Mans, Dennis Ricardo August Peters, Godefridus J. Schwartsmann, Gilberto |
dc.subject.por.fl_str_mv |
Neoplasias colorretais |
topic |
Neoplasias colorretais Colorectal carcinoma 5-Fluorouracil Irinotecan Oxaliplatin |
dc.subject.eng.fl_str_mv |
Colorectal carcinoma 5-Fluorouracil Irinotecan Oxaliplatin |
description |
Colorectal cancer is one of the most frequent malignancies in humans and an important cause of cancer death. Metastatic colorectal cancer remains incurable with available systemic therapeutic options. The most active cytotoxic drug against this malignancy, the antimetabolite 5-fluorouracil, was developed more than forty years ago, and as a single agent produces responses in only 10 to 15% of patients which in general last less than one year. Efforts to ameliorate these poor results resulted in the 5-fluorouracil/leucovorin combination, which enhances response rates about two-fold, without, however, significantly improving survival rates. The recent emergence of a handful of new 5- fluorouracil analogues and folate antagonists, as well as the topoisomerase I inhibitor irinotecan, and the third-generation platinum compound oxaliplatin, is likely to alter this gloomy scenario. These agents are at least as effective as 5-fluorouracil in patients with advanced colorectal carcinoma, both untreated and previously treated with 5- fluorouracil-based regimens. This has led to the approval of irinotecan as second-line treatment for 5-fluorouracil-refractory disease, while the use of oxaliplatin has been suggested for patients having a defective 5-fluorouracil catabolism. Recently, FDA approved the combination of irinotecan with 5-fluorouracil and leucovorin for first-line treatment of advanced colon cancer. Based on the synergistic preclinical antitumor effects of some of these agents, their meaningful singleagent activity, distinct mechanisms of cytotoxicity and resistance, and only partially overlapping toxicity profiles, effective combination regimens are now being developed, which are likely to lead to a new, more hopeful era for patients suffering from advanced colorectal carcinoma. |
publishDate |
2001 |
dc.date.issued.fl_str_mv |
2001 |
dc.date.accessioned.fl_str_mv |
2010-04-24T04:15:33Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/other |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/21166 |
dc.identifier.issn.pt_BR.fl_str_mv |
0100-879X |
dc.identifier.nrb.pt_BR.fl_str_mv |
000341742 |
identifier_str_mv |
0100-879X 000341742 |
url |
http://hdl.handle.net/10183/21166 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.ispartof.pt_BR.fl_str_mv |
Brazilian journal of medical and biological research. Ribeirão Preto, SP. Vol. 34, no. 9 (Sept. 2001), p. 1087-1103 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/21166/1/000341742.pdf http://www.lume.ufrgs.br/bitstream/10183/21166/2/000341742.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/21166/3/000341742.pdf.jpg |
bitstream.checksum.fl_str_mv |
26f56908bce4169f52adaeefe6a1107e e49979af593af239a2ca0b8dd720e168 8af6ac8c67a140350fdd161aa5d8bbf5 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1801224710536560640 |